Paul Paik
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Paul Paik as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:07 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07619339 · A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerMemorial Sloan Kettering Cancer Center · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT05607108 · A Study of ZEN003694 in People With Squamous Cell Lung CancerMemorial Sloan Kettering Cancer Center · recruiting · Squamous Cell Lung Cancer · principal investigator
- Ph2NCT05275673 · A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerFaeth Therapeutics · terminated · Non-Small Cell Lung Cancer, Squamous Non-small-cell Lung Cancer, Squamous Non-Small Cell Neoplasm of Lung · principal investigator
- Ph2NCT04991025 · Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryMemorial Sloan Kettering Cancer Center · recruiting · Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III · principal investigator
- Ph2NCT02525653 · Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung CancersMemorial Sloan Kettering Cancer Center · completed · Lung Cancer, Untreated Stage IV or Recurrent Squamous Cell Lung Cancers · principal investigator
- Ph1NCT02120807 · Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung AdenocarcinomasMemorial Sloan Kettering Cancer Center · completed · Stage IV Lung Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC PatientsR01CA255639 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2021 to 2023 · $581,481 awarded in 2023Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:07 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.N Engl J Med · 2020725 citationsRCR 29.0
- 117 citationsRCR 8.6
- Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.J Thorac Oncol · 2013110 citationsRCR 2.5
- Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.Clin Cancer Res · 202291 citationsRCR 6.2
- An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer.Lung Cancer · 201921 citationsRCR 0.8
- A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.Cancer Chemother Pharmacol · 201120 citationsRCR 0.5
- Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Cancer Sci · 202411 citationsRCR 1.4
- Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.Br J Cancer · 20247 citationsRCR 0.9
- Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.Clin Cancer Res · 20257 citationsRCR 1.6